Painful Intercourse: When to See a Doctor and What It Could Mean

What Dyspareunia Actually Means

Dyspareunia is the medical term for recurrent or persistent genital pain that occurs just before, during, or after intercourse. It is not a diagnosis by itself but rather a symptom that points toward an underlying cause. Clinicians divide it into two broad categories: superficial (felt at the vaginal opening or vulva) and deep (felt in the pelvis during thrusting).

The distinction matters because each type maps to a different set of conditions. Superficial dyspareunia often originates from skin disorders, infections, muscle tension, or hormonal changes at the vulvovaginal tissue level. Deep dyspareunia more frequently involves pelvic pathology such as endometriosis, adenomyosis, or pelvic adhesions 1. A 2014 systematic review published in BJOG found that deep dyspareunia predicted endometriosis with a positive likelihood ratio of 2.1, making it one of the more useful symptom-based indicators for the disease 2.

Pain during sex can also affect men. Conditions like phimosis, Peyronie disease, chronic prostatitis, and post-surgical scarring all cause male dyspareunia, though research on male sexual pain remains limited compared to studies in women 3.

How Common Is Painful Intercourse?

Dyspareunia is far more prevalent than most people assume. Population-based surveys consistently report that 10 to 20 percent of women experience it at some point during their reproductive years, and the numbers climb after menopause.

A landmark 2003 survey published in the American Journal of Obstetrics & Gynecology (N=3,017) found that 18.3 percent of U.S. women aged 18 to 59 reported pain during intercourse in the past year 4. Among postmenopausal women not using hormone therapy, the prevalence can reach 45 percent according to data from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey 5. Despite these numbers, fewer than half of affected women ever raise the topic with a clinician. The 2013 VIVA (Vaginal Health: Insights, Views & Attitudes) survey found that only 4 percent of postmenopausal women identified vaginal atrophy as the cause of their symptoms, and 63 percent had never discussed the issue with a healthcare provider 6.

That reluctance leads to years of avoidable discomfort. The gap between symptom onset and diagnosis averages 2 to 3 years for conditions like vulvodynia and can exceed 7 years for endometriosis 7.

When to See a Doctor: Specific Warning Signs

Not every episode of discomfort during sex requires a medical visit. Occasional mild pain with a clear situational explanation (insufficient lubrication, new position, recent procedure) often resolves on its own. But certain patterns demand evaluation.

See a clinician within one to two weeks if you notice:

• Pain that recurs across three or more consecutive encounters
• A burning, stinging, or raw sensation at the vaginal opening that persists beyond intercourse
• New onset of deep pelvic pain during thrusting
• Dyspareunia that started after a new medication (hormonal contraceptives, aromatase inhibitors, antihistamines, or SSRIs can all reduce vaginal moisture)
• Pain accompanied by changes in vaginal discharge, odor, or irritation

Seek same-day or next-day evaluation if you experience:

• Post-coital bleeding not explained by menstruation
• Fever or chills after intercourse
• Sudden severe pelvic pain (possible ovarian torsion or ruptured cyst)
• Visible ulcers, blisters, or rapidly growing lesions on the vulva

The American College of Obstetricians and Gynecologists (ACOG) states in Practice Bulletin No. 213: "Dyspareunia that impairs quality of life or is associated with other pelvic symptoms warrants a structured evaluation including a targeted history, vulvar and vaginal inspection, single-digit palpation of the vestibule and pelvic floor, and bimanual examination" 8.

Causes of Superficial Dyspareunia

Superficial pain, localized at or near the vaginal introitus, has a specific differential diagnosis. Identifying the exact cause changes the treatment plan completely.

Vulvovaginal atrophy (genitourinary syndrome of menopause, or GSM). Declining estrogen thins the vaginal epithelium, reduces blood flow, and lowers lubrication. The North American Menopause Society (NAMS) 2020 position statement notes that GSM affects up to 84 percent of postmenopausal women and worsens progressively without treatment, unlike vasomotor symptoms that tend to fade over time 9.

Vulvodynia and provoked vestibulodynia (PVD). PVD is the most common cause of recurrent superficial dyspareunia in premenopausal women under 50. The tissue appears normal on inspection, but light touch at the vestibule reproduces sharp, burning pain. A 2012 population-based study in the Journal of Lower Genital Tract Disease estimated the lifetime prevalence at 8 percent in U.S. women 10.

Vaginismus. Involuntary contraction of the pelvic floor muscles prevents or severely limits penetration. It may be primary (lifelong) or secondary (acquired after a triggering event such as infection, trauma, or surgery).

Infections. Vulvovaginal candidiasis, bacterial vaginosis, trichomoniasis, herpes simplex, and recurrent urinary tract infections can all cause pain localized to the introitus. A simple wet prep, culture, or PCR test identifies most of these within 48 hours 11.

Dermatologic conditions. Lichen sclerosus, lichen planus, and contact dermatitis from soaps, lubricants, or laundry products cause vulvar inflammation that makes intercourse painful. Biopsy confirms the diagnosis when clinical appearance is ambiguous.

Causes of Deep Dyspareunia

Deep pain felt in the lower abdomen or pelvis during thrusting or deep penetration signals pathology beyond the vaginal canal. The differential is distinct from superficial causes.

Endometriosis. This condition affects roughly 10 percent of reproductive-age women globally, according to WHO data 12. Endometrial-like tissue growing outside the uterus triggers chronic inflammation. Deep dyspareunia correlates particularly with lesions involving the uterosacral ligaments and the cul-de-sac. The ESHRE (European Society of Human Reproduction and Embryology) guideline recommends transvaginal ultrasound as the first-line imaging modality and MRI when surgery is being planned 13.

Adenomyosis. Endometrial tissue grows into the myometrium, causing uterine enlargement, heavy bleeding, and deep pain. MRI has a sensitivity of 77 percent and specificity of 89 percent for diagnosis 14.

Pelvic inflammatory disease (PID). Ascending infection, usually from chlamydia or gonorrhea, inflames the upper genital tract. The CDC recommends empiric treatment with ceftriaxone 500 mg IM single dose plus doxycycline 100 mg orally twice daily for 14 days when clinical suspicion is moderate to high 11.

Ovarian cysts and masses. Functional cysts, endometriomas, and (rarely) neoplasms can cause deep pain, especially in certain positions. Transvaginal ultrasound is the standard initial workup.

Interstitial cystitis / bladder pain syndrome. Chronic bladder inflammation produces suprapubic pain that worsens with penetration. The American Urological Association guideline recommends a stepwise approach beginning with patient education and behavioral modification before oral medications like amitriptyline or pentosan polysulfate 15.

Pelvic adhesions. Prior surgeries, infections, or endometriosis can create scar tissue that tethers pelvic organs and restricts their normal mobility during intercourse.

How Doctors Diagnose Dyspareunia

The diagnostic workup starts with a detailed history. Your clinician will ask where the pain occurs (entry vs. deep), when it started, whether it happens with every attempt or only in certain positions, what makes it worse, and whether you have associated symptoms such as bleeding, discharge, or bowel or bladder complaints.

The physical exam follows a structured approach. Dr. Andrew Goldstein, director of the Centers for Vulvovaginal Disorders, describes the exam technique: "We use a moistened cotton swab to map the vulvar vestibule systematically, testing at the 2, 4, 6, 8, and 10 o'clock positions. This 'Q-tip test' localizes provoked pain to specific zones and distinguishes vestibulodynia from generalized vulvodynia" 10.

Single-digit palpation of the pelvic floor muscles assesses for hypertonicity, trigger points, and tenderness. A bimanual exam evaluates the uterus, adnexa, and cul-de-sac for masses, nodularity (suggestive of endometriosis), or tenderness.

Laboratory and imaging tests depend on the clinical picture:

• Vaginal pH, wet mount, and cultures or PCR panels if infection is suspected
• Serum estradiol and FSH if menopausal status is uncertain
• Transvaginal ultrasound for deep dyspareunia
• MRI when endometriosis, adenomyosis, or a complex mass needs better characterization
• Cystoscopy or urodynamics if bladder pain syndrome is suspected
• Vulvar biopsy for skin changes unresponsive to initial treatment

The goal of this workup is a specific, actionable diagnosis. "Dyspareunia" on a chart without a cause is not a complete assessment.

Treatment for Superficial Dyspareunia

Treatment depends entirely on the underlying cause. No single therapy works for all forms of painful intercourse. Here are the evidence-based options for the most common superficial causes.

For GSM / vulvovaginal atrophy. Low-dose vaginal estrogen is the gold standard. A 2019 Cochrane review of 30 RCTs (N=6,235) found that vaginal estrogen preparations (cream, tablet, or ring) all significantly improved dyspareunia scores compared with placebo, with no clinically meaningful differences between formulations 16. The 10 mcg estradiol vaginal tablet (Vagifem) and the 7.5 mcg/24h estradiol ring (Estring) produce minimal systemic absorption, keeping serum estradiol within the normal postmenopausal range 9.

For women who cannot or prefer not to use estrogen, ospemifene (Osphena) 60 mg daily is an oral SERM approved specifically for dyspareunia due to GSM. In the phase III trial (N=826), ospemifene reduced pain severity by 1.5 points on a 4-point scale vs. 1.2 for placebo at 12 weeks (P<0.001) 17. Intravaginal DHEA (prasterone, Intrarosa) 6.5 mg daily is another non-estrogen option backed by a phase III trial showing a 1.27-point reduction in dyspareunia severity vs. 0.87 for placebo at 12 weeks 18.

For provoked vestibulodynia (PVD). Treatment is multimodal. Pelvic floor physical therapy is the cornerstone. A 2019 randomized trial in Obstetrics & Gynecology (N=212) found that 12 sessions of pelvic floor PT produced a 50 percent pain reduction in 70 percent of participants, with benefits maintained at 6-month follow-up 19. Topical treatments such as lidocaine 5% ointment applied nightly can reduce pain during intercourse, though results from controlled trials have been mixed. Cognitive behavioral therapy (CBT) addresses the central sensitization and pain catastrophizing that maintain the condition. A 2016 RCT comparing CBT, topical corticosteroid, and surgery for PVD found CBT noninferior to surgery at 6 months for pain during intercourse 20.

For vaginismus. Graded vaginal dilator therapy combined with pelvic floor PT has success rates near 80 percent in structured programs 21. Botulinum toxin A injections into the levator ani muscles are used off-label for refractory cases, with small trials reporting significant improvement in penetration ability 22.

For infections. Treat the specific pathogen. Fluconazole 150 mg single dose for uncomplicated vulvovaginal candidiasis. Metronidazole 500 mg twice daily for 7 days for bacterial vaginosis. Doxycycline plus ceftriaxone for PID. Recurrent candidiasis (four or more episodes per year) may need a 6-month fluconazole suppression regimen at 150 mg weekly 11.

Treatment for Deep Dyspareunia

Deep dyspareunia requires addressing the pelvic pathology generating the pain signal.

Endometriosis. Hormonal suppression is the first-line medical approach. Combined oral contraceptives taken continuously (no placebo week), progestins (dienogest 2 mg daily or norethindrone acetate 5 mg daily), and GnRH antagonists (elagolix) all reduce endometriosis-associated dyspareunia. The ELARIS EM-I trial (N=872) demonstrated that elagolix 200 mg twice daily reduced dyspareunia scores by 53.4 percent vs. 36.5 percent for placebo at 3 months 23. Laparoscopic excision of endometriotic lesions provides longer-lasting relief, with a 2014 Cochrane review confirming that surgical treatment improves pain compared with diagnostic laparoscopy alone 24.

Adenomyosis. Hormonal options overlap with endometriosis management. The levonorgestrel-releasing intrauterine system (Mirena) reduces adenomyosis-related pain and bleeding and is recommended as a first-line treatment by NICE guidelines. Hysterectomy remains the definitive cure for women who have completed childbearing.

Pelvic adhesions. Adhesiolysis can be performed laparoscopically, though recurrence rates are high (up to 70 percent in some series). Barrier agents like Seprafilm may reduce but not eliminate re-formation.

Interstitial cystitis. Amitriptyline 25 to 75 mg at bedtime reduced symptoms in 64 percent of patients in a randomized controlled trial (N=271) published in the Journal of Urology 25. Bladder instillations with dimethyl sulfoxide (DMSO) are FDA-approved for this indication.

The Role of Pelvic Floor Physical Therapy

Pelvic floor dysfunction either causes or aggravates a large percentage of dyspareunia cases. Even when another condition (endometriosis, atrophy, infection) is the primary driver, secondary pelvic floor muscle guarding often develops and maintains pain after the original trigger is treated.

A 2021 systematic review and meta-analysis in Physical Therapy pooled 10 RCTs (N=682) and found that pelvic floor physiotherapy produced a standardized mean difference of -0.77 (95% CI: -1.07 to -0.47) for sexual pain outcomes, a moderate-to-large effect size 26. Techniques include internal and external myofascial release, biofeedback, dilator training, and education about pain neuroscience.

Treatment courses typically run 8 to 16 sessions over 3 to 6 months. Many patients report meaningful improvement by sessions 4 to 6. Home exercises (diaphragmatic breathing, progressive relaxation, dilator use) reinforce gains between sessions.

Pelvic floor PT is underused. A 2022 survey in the Journal of Sexual Medicine found that only 32 percent of gynecologists routinely referred dyspareunia patients to pelvic floor physical therapy, despite Level I evidence supporting its efficacy 27.

Psychological and Relationship Factors

Chronic painful intercourse affects mental health and partnerships. A 2015 study in Pain (N=101 couples) found that women with PVD had significantly higher rates of anxiety (38 percent) and depression (22 percent) than age-matched controls 28. Partner responses shaped outcomes: empathic but solution-focused responses correlated with lower pain intensity, while solicitous (overly sympathetic) or hostile responses predicted worse outcomes.

Sex therapy and couples counseling are adjuncts, not replacements, for medical treatment. The combination of medical management plus CBT consistently outperforms either alone in trials of PVD and vulvodynia. Dr. Caroline Pukall, a leading researcher at Queen's University, has noted: "We see the best results when we treat dyspareunia as a biopsychosocial condition. Addressing the tissue pathology alone without managing the pain-related fear and avoidance behaviors often leaves patients only partially improved" 20.

What to Expect at Your First Appointment

Knowing what a dyspareunia evaluation involves can reduce anxiety about the visit. Your clinician will typically spend 10 to 15 minutes on history, asking about pain location, timing, associated symptoms, menstrual history, surgical history, sexual history, and current medications. You can prepare by noting when the pain started, what it feels like, and what makes it better or worse.

The physical exam usually includes visual inspection of the vulva, the cotton-swab test of the vestibule, speculum exam to visualize the vaginal walls and cervix, and bimanual palpation. Single-digit exams are used initially to minimize discomfort. If the exam itself is too painful, your clinician may apply topical lidocaine jelly and wait 5 to 10 minutes before proceeding, or they may defer part of the exam and schedule a follow-up.

Expect to leave with either a working diagnosis and treatment plan or a clear set of next steps (lab tests, imaging, specialist referral). If your provider attributes the pain to "not enough foreplay" or "just relax" without a physical exam, seek a second opinion. Dyspareunia has identifiable causes, and dismissal is not a diagnosis.